Advanced Filters
noise

Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,124 clinical trials
M Mohamed BOUATTOUR, Dr

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common liver primary cancer with a high rate of mortality. Since the results of IMbrave150, immunotherapy have emerged as a standard of care for HCC patients advanced and/or unresectable in first line of treatment. The objective response rate was about 30%, but half of …

18 years of age All Phase 2
H Hao Zhuang, M.D.

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

Currently, it has been demonstrated that CDK4 is highly expressed in hepatocellular carcinoma patients and is significantly associated with poor prognosis in hepatocellular carcinoma patients. Palbociclib is the world's first marketed inhibitor of the cell cycle protein-dependent kinase CDK4/6, which is capable of blocking cell cycle progression and inhibiting tumor …

18 - 75 years of age All Phase N/A
C Changzhen Shang, MD

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.

18 - 75 years of age All Phase N/A

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of …

18 - 18 years of age All Phase N/A

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study to explore the efficacy and safety of the new second-line treatment for advanced HCC. As a …

18 years of age All Phase 2

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.

18 years of age All Phase 2
V Victor GAILLARD

Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs

The aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice.

18 years of age All Phase N/A
S Shuxian An

Target-specific immunoPET Imaging of Digestive System Carcinoma

The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.

18 - 75 years of age All Phase N/A
W Wan-guang Zhang, M.D.

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

18 - 75 years of age All Phase 4
Z Zhang Zhenfeng, MD, PhD

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.

18 - 75 years of age All Phase 2

Simplify language using AI